The obesity space may have another serious entry as Terns Pharmaceuticals, Inc. unveiled Phase I data for its oral, daily GLP-1 agonist TERN-601 on 9 September that indicate competitive weight-loss performance at 28 days with a clean safety and tolerability profile. Terns is working to move TERN-601 quickly into Phase II in 2025.
Terns’ Early Data May Position It Well In GLP-1 Obesity Race
In a multiple-ascending dose Phase I trial, Terns’ oral GLP-1 agonist showed 4.9% placebo-adjusted weight loss at 28 weeks, with no severe gastrointestinal side effects.
More from Clinical Trials
• By
Compass' bispecific antibody tovecimig hits primary efficacy endpoint in Phase II/III top-line data in advanced biliary tract cancer, and may have class side-effect advantages. But additional survival data may be needed to support US approval.
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
With new Phase II data, Edgewise asserted that EDG-7500, a sarcomere modulator, could offer better efficacy and safety than cardiac myosin inhibitors in hypertrophic cardiomyopathy.
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.